A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
收藏DataCite Commons2025-10-17 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00004487/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared to paclitaxel plus placebo.
提供机构：
Vivli
创建时间：
2019-09-09
